From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
There is no established relationship between biting and prostate cancer, as the current evidence does not support a direct link between the two. The provided studies focus on the diagnosis, treatment, and management of prostate cancer, with no mention of biting as a factor. Key considerations in prostate cancer treatment include the stage and aggressiveness of the cancer, as well as the patient's age, overall health, and personal preferences 1. Treatment options may include surgery, radiation therapy, and hormone therapy, with the goal of minimizing treatment-related complications while maximizing benefits 2. Regular prostate-specific antigen (PSA) blood tests and digital rectal exams are crucial for early detection, as prostate cancer is often asymptomatic in its early stages 3. In the absence of evidence linking biting to prostate cancer, the focus should remain on established risk factors and screening methods to improve outcomes and reduce mortality. Some studies discuss the importance of risk stratification and biomarkers in prostate cancer management, but none mention biting as a relevant factor 4, 5. Overall, the current evidence prioritizes traditional screening and treatment approaches over unproven factors like biting.